Cagrilintide dosing schedule
> Updated:
Calculate the Cagrilintide dose
The calculator is already set up for Cagrilintide — adjust the dose or diluent volume for your vial.
Human dosing
Cagrilintide is searched together with "dosage" mostly because of the step-up schedule itself: the table below shows each titration step separately rather than one "standard" dose.
| Period / condition | Dose | Escalation |
|---|---|---|
| Weeks 1–4 | 0.25 mg weekly SubQ | Starting dose |
| Weeks 5–12 | 0.5 → 1.0 mg weekly | Increase every 4 weeks |
| Weeks 13–16 | 1.7 mg weekly | Increase if needed |
| From week 17 | 2.4 mg weekly | Maximum in this schedule |
Practical dosage and effect notes
In a trial by Lau and colleagues (The Lancet, 2021), 706 participants with overweight or obesity received cagrilintide subcutaneously once weekly at five doses: 0.3, 0.6, 1.2, 2.4, and 4.5 mg, after up to a 6-week titration period, over 26 weeks. The effect was dose-dependent: the higher the dose, the greater the weight reduction, and the top 4.5 mg level produced an average 10.8% loss (11.5 kg).
The schedule on this page tops out at 2.4 mg weekly: the trial used that same dose as a plateau step before any move to the highest level, raising the dose gradually every 4 weeks instead of the trial's 6. The slower step is meant to further reduce nausea and constipation, the most common adverse reactions in the same trial (41–63% of participants depending on dose).
This is background for planning a research protocol, not a medical recommendation and not instructions for self-administration.
How to reconstitute
An example reconstitution for convenient dosing. The exact ratios depend on your vial. For research reference only — not medical guidance.
- 1Add the diluentUse bacteriostatic water. Example: 2 ml into a 10 mg vial.Cagrilintide10 mg+ 2 mlDiluent
- 2Get the concentrationExample: 10 mg in 2 ml =Cagrilintide5 mg/ml(5,000 mcg/ml)
- 3Work out the volume per doseFor example, for a 0.25 mg dose:0.25 mg = 0.05 ml= 5 u. (U-100)
This is only an example calculation. You can use a different diluent volume — plug your own numbers into the calculator. Open calculator →
Research protocols
Cagrilintide: reference regimens
Cagrilintide (an amylin analog) is administered subcutaneously once weekly with gradual dose escalation in studies.
More scientific background in the Cagrilintide monograph
Notes and safety
- • Cagrilintide is a research peptide. Human safety and efficacy data are limited.
- • The regimens shown are based on publications and research protocols, not clinical recommendations.
- • Individual reactions may vary. Published protocols typically start dosing at the lower end of the reported range.
- • Not recommended for use with chronic illness, pregnancy, or breastfeeding.
- • This information is for educational purposes and is not medical advice.
Cagrilintide